目录号: HY-14779
Riociguat 是一种可口服的可溶性鸟苷酸环化酶(sGC) 刺激剂，常用于治疗肺动脉高压症。
相关产品
Lificiguat-Linaclotide-Cinaciguat-BAY 41-2272-Vericiguat-
生物活性
Description
Riociguat is an oral stimulator of soluble guanylate cyclase (sGC), and used in the treatment of pulmonary hypertension.
In Vitro
Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100?μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism[1].?Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes[2].
In Vivo
Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats[1].
Clinical Trial
Dinesh Khanna, MD, MS-Bayer-University of Michigan
Scleroderma-Digital Ulcers
September 2016
Phase 2
Bayer
Hypertension, Pulmonary
July 16, 2014
Richard Moon-Duke University
Hypertension, Pulmonary-Altitude Sickness
January 2014
Phase 4
Gregory J. Kato, MD-University of Pittsburgh
Sickle Cell Disease
April 11, 2017
Phase 2
Bayer
Hypertension, Pulmonary
June 29, 2015
Medical University of Vienna
Hypertension, Pulmonary-Heart Failure With Normal Ejection Fraction
March 2016
Phase 2
Bayer
Hypertension, Pulmonary
February 2014
Phase 3
Assistance Publique - Hôpitaux de Paris-Bayer
Chronic Thromboembolic Pulmonary Hypertension
January 2016
Bayer
Pharmacology, Clinical
March 2009
Phase 1
University of Cincinnati
Sarcoidosis
April 2015
Phase 4
Bayer-Merck Sharp & Dohme Corp.
Hypertension, Pulmonary
October 29, 2015
Phase 3
Bayer
Pulmonary Hypertension
August 2010
Phase 2
Bayer
Coronary Artery Disease
May 2012
Phase 2
Bayer
Scleroderma, Systemic
January 15, 2015
Phase 2
Bayer
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
June 4, 2014
Phase 2
Bayer
Drug Interactions
June 2014
Phase 1
Bayer
Hypertension, Pulmonary-Ventricular Dysfunction, Left
November 2010
Phase 2
Bayer
Hypertension, Pulmonary
June 16, 2016
Phase 4
Bayer
Hypertension, Pulmonary
Bayer
Hypertension, Pulmonary
May 31, 2014
Bayer
Pulmonary Arterial Hypertension
January 12, 2017
Phase 4
Bayer
Hypertension, Pulmonary-Ventricular Dysfunction, Left
April 14, 2010
Phase 2
Bayer
Hypertension, Pulmonary-Pulmonary Disease, Chronic Obstructive
August 2008
Phase 1
Bayer
Pulmonary Hypertension
February 2009
Phase 3
Bayer
Healthy Volunteers
June 2014
Phase 1
Bayer
Hypertension, Pulmonary
September 15, 2015
Bayer
Hypertension, Pulmonary-Ventricular Dysfunction, Left
July 2010
Phase 2
Bayer
Pulmonary Hypertension
December 2008
Phase 3
Bayer-Merck Sharp & Dohme Corp.
Cystic Fibrosis
September 30, 2014
Phase 2
Bayer
Pulmonary Hypertension
July 1, 2009
Phase 3
Bayer
Hypertension, Pulmonary
March 12, 2009
Phase 3
Bayer
Hypertension, Pulmonary
August 2, 2008
Phase 2
Bayer
Raynaud Disease
October 2013
Phase 2
Bayer
Hypertension, Pulmonary
January 2007
Phase 2
Bayer
Hypertension, Pulmonary
October 2008
Phase 1
Bayer
Hypertension, Pulmonary
September 2014
Phase 4
Bayer
HIV-DDI
February 2016
Phase 1
Bayer
Pharmacology, Clinical
January 2012
Phase 1
Medical University of Vienna
Chronic Thromboembolic Pulmonary Hypertension-Sleep Disordered Breathing
February 1, 2017
View MoreCollapse
References
